L-6-[18F]Fluoro-DOPA Metabolism in Monkeys and Humans: Biochemical Parameters for the Formulation of Tracer Kinetic Models with Positron Emission Tomography

Characterization of peripheral and cerebral l-3,4-dihydroxy-6-[18F]fluorophenylalanine (FDOPA) metabolism in humans and monkeys has shown FDOPA to be an analogue of l-DOPA for the study of the dopaminergic system with positron emission tomography (PET). In human studies with carbidopa pretreatment, l-3,4-dihydroxy-6-[18F]fluoro-3-O-methylphenylalanine (3-OMFD) was the only FDOPA metabolite detected in plasma. FDOPA administration in monkeys resulted in selective accumulation of FDOPA metabolites in central dopaminergic regions, whereas 3-OMFD of peripheral origin was uniformly distributed among putamen, caudate, frontal cortex, and cerebellum. At 60 min, 3-OMFD and 6-[18F]fluorodopamine (FDA) each represented ∼35% of the total activity, the remainder being FDOPA and FDA metabolites. These data on monkey and human FDOPA metabolism provide the basis for the configuration of an FDOPA tracer kinetic model with PET.

[1]  P. Cumming,et al.  Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. , 1986, Life sciences.

[2]  Michael J. Adam,et al.  Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.

[3]  J. Mazziotta,et al.  Positron emission tomography and autoradiography: Principles and applications for the brain and heart , 1985 .

[4]  C. Nahmias,et al.  Metabolites of 6-[18F]fluoro-L-dopa in human blood. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Michael E. Phelps,et al.  Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET. , 1990 .

[6]  R. Roth,et al.  Mesocortical dopamine neurons: rapid transmitter turnover compared to other brain catecholamine systems. , 1981, Brain research.

[7]  J. Barrio,et al.  In vivo assessment of neurotransmitter biochemistry in humans. , 1988, Annual review of pharmacology and toxicology.

[8]  Scott T. Grafton,et al.  Kinetics and Modeling of l-6-[18F]Fluoro-DOPA in Human Positron Emission Tomographic Studies , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  A. Gjedde,et al.  Blood—Brain Transfer and Metabolism of 6-[18F]Fluoro-L-DOPA in Rat , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  K. Kirk,et al.  The chemistry and biology of ring‐fluorinated biogenic amines , 1984, Medicinal research reviews.

[11]  M E Phelps,et al.  Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET. , 1990, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[12]  C Nahmias,et al.  Cerebral Metabolism of 6–[18F]Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Primate , 1987, Journal of neurochemistry.

[13]  N. Weiner,et al.  The effect of nerve stimulation on the synthesis and metabolism of norepinephrine in the isolated guinea-pig hypogastric nerve-vas deferens preparation. , 1968, The Journal of pharmacology and experimental therapeutics.

[14]  J. Hoffman,et al.  6-[18F]Fluoro-l-DOPA metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomography , 1991, Brain Research.

[15]  A. Luxen,et al.  The effects of carbidopa on the metabolism of 6-[18F]fluoro-L-dopa in rats, monkeys and humans. , 1990, Life sciences.

[16]  B. Berger,et al.  Catecholamine innervation of the human cerebral cortex as revealed by comparative immunohistochemistry of tyrosine hydroxylase and dopamine‐beta‐hydroxylase , 1989, The Journal of comparative neurology.

[17]  M. Häusser,et al.  Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat. , 1988, Biochemical pharmacology.

[18]  A. Luxen,et al.  Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats. , 1990, Biochemical pharmacology.

[19]  K. Kirk,et al.  The effect of ring-fluorination on the rate of O-methylation of dihydroxyphenylalanine (DOPA) by catechol-O-methyltransferase: significance in the development of 18F-PETT scanning agents. , 1985, Biochemical and biophysical research communications.

[20]  B. Berger,et al.  Regional and laminar distribution of the dopamine and serotonin innervation in the macaque cerebral cortex: A radioautographic study , 1988, The Journal of comparative neurology.

[21]  W. Landau.  Clinical Neuromythology IV — Reflex dementia , 1989, Neurology.

[22]  A. Luxen,et al.  Fluorination of substituted veratroles via regioselective mercuration , 1988 .

[23]  I. Kopin,et al.  6-Fluorocatecholamines as false adrenergic neurotransmitters. , 1983, The Journal of pharmacology and experimental therapeutics.

[24]  A. Lang,et al.  Striatal dopamine distribution in Parkinsonian patients during life , 1985, Journal of the Neurological Sciences.

[25]  O. Hornykiewicz,et al.  OCCURRENCE AND DISTRIBUTION OF AROMATIC l‐AMINO ACID (l‐DOPA) DECARBOXYLASE IN THE HUMAN BRAIN , 1972, Journal of neurochemistry.

[26]  E. Mcgeer,et al.  The Metabolism of [18F]6‐Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Hooded Rat , 1987, Journal of neurochemistry.

[27]  C. Patlak,et al.  Nigrostriatal function in humans studied with positron emission tomography , 1989, Annals of neurology.

[28]  Richard S. J. Frackowiak,et al.  PET and movement disorders. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[29]  T Jones,et al.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.